Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIDOPAN: IV Lidocaine for Pancreatic Pain
NCT05906615Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Jan 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lidocaine Hydrochloride Injection, without epinephrine in pancreatic cancer (PC) and chronic pancreatitis (CP), sponsored by University of Amsterdam. Primary endpoint: Pain score (NRS/BPI) at Day 1. Started Jan 2021; status: completed.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
pancreatic cancer (PC)chronic pancreatitis (CP)
Beyond the preview
Go deeper on NCT05906615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906615.